Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management.

Kolotkin RL, Fujioka K, Wolden ML, Brett JH, Bjorner JB

Clinical obesity19 May 2016Cited by 30 (Europe PMC)

PMID27198973PMCIDPMC5084798DOI10.1111/cob.12146PepBankPUB-27198973

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with obesity or overweight with comorbidity, liraglutide 3.0 mg improved the IWQOL-Lite total score more than placebo.
In plain wordsIn adults with obesity or overweight, liraglutide 3.0 mg improved weight-related quality of life more than placebo.
Peptide
Liraglutide
Outcome
IncreaseIWQOL-Lite total score improvement
Study
n = 3,066
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
3.0 mg · subcutaneousAs given in this study (human).
Measurements
Estimated treatment difference, IWQOL-Lite total score
3.1 points
95% CI 2.2 to 4.0
Source sentences
Summary
The estimated treatment differences were IWQOL-Lite total score 3.1 (95% CI: 2.2; 4.0), P < 0.0001; SF-36 PCS 1.7 (95% CI: 1.2; 2.2), P < 0.0001 and MCS 0.9 (95% CI: 0.3; 1.5), P = 0.003.
3 context sentences(design, population, supporting numbers)
Summary · context
Individuals on liraglutide 3.0 mg (n = 2046) had significantly greater improvements in IWQOL-Lite total score (10.6 ± 13.3) vs. placebo (n = 1020) (7.7 ± 12.8) and SF-36 physical (PCS) and mental (MCS) component summary scores (PCS, 3.6 ± 6.8; MCS, 0.2 ± 8.1) vs. placebo (PCS, 2.2 ± 7.7; MCS, -0.9 ± 9.1).
Summary · context
The SCALE Obesity and Prediabetes study investigated the effect of liraglutide 3.0 mg, as adjunct to diet and exercise, on HRQoL in patients with obesity [body mass index (BMI) ≥ 30 kg m(-2) ] or overweight (BMI ≥ 27 kg m(-2) ) with comorbidity.
Summary · context
Participants were advised on a 500 kcal d(-1) deficit diet and a 150-min week(-1) exercise programme and were randomised 2:1 to once-daily subcutaneous liraglutide 3.0 mg or placebo.
Report a problemFND-2719897301
02HumanRandomized controlled trialEfficacy outcome
In adults with obesity or overweight with comorbidity, liraglutide 3.0 mg improved the SF-36 physical component summary score more than placebo.
In plain wordsIn adults with obesity or overweight, liraglutide 3.0 mg improved the physical health quality-of-life score more than placebo.
Peptide
Liraglutide
Outcome
IncreaseSF-36 physical component summary score
Study
n = 3,066
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
3.0 mg · subcutaneousAs given in this study (human).
Measurements
Estimated treatment difference, SF-36 PCS
1.7 points
95% CI 1.2 to 2.2
Source sentences
Summary
The estimated treatment differences were IWQOL-Lite total score 3.1 (95% CI: 2.2; 4.0), P < 0.0001; SF-36 PCS 1.7 (95% CI: 1.2; 2.2), P < 0.0001 and MCS 0.9 (95% CI: 0.3; 1.5), P = 0.003.
3 context sentences(design, population, supporting numbers)
Summary · context
Individuals on liraglutide 3.0 mg (n = 2046) had significantly greater improvements in IWQOL-Lite total score (10.6 ± 13.3) vs. placebo (n = 1020) (7.7 ± 12.8) and SF-36 physical (PCS) and mental (MCS) component summary scores (PCS, 3.6 ± 6.8; MCS, 0.2 ± 8.1) vs. placebo (PCS, 2.2 ± 7.7; MCS, -0.9 ± 9.1).
Summary · context
The SCALE Obesity and Prediabetes study investigated the effect of liraglutide 3.0 mg, as adjunct to diet and exercise, on HRQoL in patients with obesity [body mass index (BMI) ≥ 30 kg m(-2) ] or overweight (BMI ≥ 27 kg m(-2) ) with comorbidity.
Summary · context
Participants were advised on a 500 kcal d(-1) deficit diet and a 150-min week(-1) exercise programme and were randomised 2:1 to once-daily subcutaneous liraglutide 3.0 mg or placebo.
Report a problemFND-2719897302
03HumanRandomized controlled trialEfficacy outcome
In adults with obesity or overweight with comorbidity, liraglutide 3.0 mg improved the SF-36 mental component summary score more than placebo.
In plain wordsIn adults with obesity or overweight, liraglutide 3.0 mg improved the mental health quality-of-life score more than placebo.
Peptide
Liraglutide
Outcome
IncreaseSF-36 mental component summary score
Study
n = 3,066
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
3.0 mg · subcutaneousAs given in this study (human).
Measurements
Estimated treatment difference, SF-36 MCS
0.9 points
95% CI 0.3 to 1.5
Source sentences
Summary
The estimated treatment differences were IWQOL-Lite total score 3.1 (95% CI: 2.2; 4.0), P < 0.0001; SF-36 PCS 1.7 (95% CI: 1.2; 2.2), P < 0.0001 and MCS 0.9 (95% CI: 0.3; 1.5), P = 0.003.
3 context sentences(design, population, supporting numbers)
Summary · context
Individuals on liraglutide 3.0 mg (n = 2046) had significantly greater improvements in IWQOL-Lite total score (10.6 ± 13.3) vs. placebo (n = 1020) (7.7 ± 12.8) and SF-36 physical (PCS) and mental (MCS) component summary scores (PCS, 3.6 ± 6.8; MCS, 0.2 ± 8.1) vs. placebo (PCS, 2.2 ± 7.7; MCS, -0.9 ± 9.1).
Summary · context
The SCALE Obesity and Prediabetes study investigated the effect of liraglutide 3.0 mg, as adjunct to diet and exercise, on HRQoL in patients with obesity [body mass index (BMI) ≥ 30 kg m(-2) ] or overweight (BMI ≥ 27 kg m(-2) ) with comorbidity.
Summary · context
Participants were advised on a 500 kcal d(-1) deficit diet and a 150-min week(-1) exercise programme and were randomised 2:1 to once-daily subcutaneous liraglutide 3.0 mg or placebo.
Report a problemFND-2719897303
04HumanRandomized controlled trialEfficacy outcome
In adults with obesity or overweight with comorbidity, all IWQOL-Lite subscales improved significantly with liraglutide 3.0 mg versus placebo.
In plain wordsIn adults with obesity or overweight, every part of the weight-related quality-of-life questionnaire improved more with liraglutide 3.0 mg than with placebo.
Peptide
Liraglutide
Outcome
IncreaseIWQOL-Lite subscales
Study
n = 3,066
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
3.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
All subscales of the IWQOL-Lite and SF-36 were significantly improved with liraglutide 3.0 mg vs. placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
The SCALE Obesity and Prediabetes study investigated the effect of liraglutide 3.0 mg, as adjunct to diet and exercise, on HRQoL in patients with obesity [body mass index (BMI) ≥ 30 kg m(-2) ] or overweight (BMI ≥ 27 kg m(-2) ) with comorbidity.
Summary · context
Participants were advised on a 500 kcal d(-1) deficit diet and a 150-min week(-1) exercise programme and were randomised 2:1 to once-daily subcutaneous liraglutide 3.0 mg or placebo.
Report a problemFND-2719897304
05HumanRandomized controlled trialEfficacy outcome
In adults with obesity or overweight with comorbidity, all SF-36 subscales improved significantly with liraglutide 3.0 mg versus placebo.
In plain wordsIn adults with obesity or overweight, every part of the general health questionnaire improved more with liraglutide 3.0 mg than with placebo.
Peptide
Liraglutide
Outcome
IncreaseSF-36 subscales
Study
n = 3,066
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
3.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
All subscales of the IWQOL-Lite and SF-36 were significantly improved with liraglutide 3.0 mg vs. placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
The SCALE Obesity and Prediabetes study investigated the effect of liraglutide 3.0 mg, as adjunct to diet and exercise, on HRQoL in patients with obesity [body mass index (BMI) ≥ 30 kg m(-2) ] or overweight (BMI ≥ 27 kg m(-2) ) with comorbidity.
Summary · context
Participants were advised on a 500 kcal d(-1) deficit diet and a 150-min week(-1) exercise programme and were randomised 2:1 to once-daily subcutaneous liraglutide 3.0 mg or placebo.
Report a problemFND-2719897305
06HumanRandomized controlled trialEfficacy outcome
In adults with obesity or overweight with comorbidity, more patients on liraglutide 3.0 mg than on placebo had a meaningful improvement in IWQOL-Lite total score.
In plain wordsIn adults with obesity or overweight, more people on liraglutide 3.0 mg than on placebo had a clear quality-of-life gain.
Peptide
Liraglutide
Outcome
IncreaseMeaningful improvement in IWQOL-Lite total score
Study
n = 3,066
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
3.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
More patients on liraglutide 3.0 mg experienced meaningful improvement on the IWQOL-Lite total (P < 0.0001) and the SF-36 PCS (P < 0.0001) scores.
2 context sentences(design, population, supporting numbers)
Summary · context
The SCALE Obesity and Prediabetes study investigated the effect of liraglutide 3.0 mg, as adjunct to diet and exercise, on HRQoL in patients with obesity [body mass index (BMI) ≥ 30 kg m(-2) ] or overweight (BMI ≥ 27 kg m(-2) ) with comorbidity.
Summary · context
Participants were advised on a 500 kcal d(-1) deficit diet and a 150-min week(-1) exercise programme and were randomised 2:1 to once-daily subcutaneous liraglutide 3.0 mg or placebo.
Report a problemFND-2719897306
07HumanRandomized controlled trialEfficacy outcome
In adults with obesity or overweight with comorbidity, more patients on liraglutide 3.0 mg than on placebo had a meaningful improvement in SF-36 PCS score.
In plain wordsIn adults with obesity or overweight, more people on liraglutide 3.0 mg than on placebo had a clear gain in physical health score.
Peptide
Liraglutide
Outcome
IncreaseMeaningful improvement in SF-36 PCS score
Study
n = 3,066
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
3.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
More patients on liraglutide 3.0 mg experienced meaningful improvement on the IWQOL-Lite total (P < 0.0001) and the SF-36 PCS (P < 0.0001) scores.
2 context sentences(design, population, supporting numbers)
Summary · context
The SCALE Obesity and Prediabetes study investigated the effect of liraglutide 3.0 mg, as adjunct to diet and exercise, on HRQoL in patients with obesity [body mass index (BMI) ≥ 30 kg m(-2) ] or overweight (BMI ≥ 27 kg m(-2) ) with comorbidity.
Summary · context
Participants were advised on a 500 kcal d(-1) deficit diet and a 150-min week(-1) exercise programme and were randomised 2:1 to once-daily subcutaneous liraglutide 3.0 mg or placebo.
Report a problemFND-2719897307

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01272219

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

Novo Nordisk A/Sn = 3,7311 Jun 2011 to 2 Mar 2015

Metabolism and Nutrition Disorder · Obesity

Trial page ClinicalTrials.govUpdated 19 Jan 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.